ULTRAGENYX PHARMACEUTICAL INC. Proceeds from (Payments for) Other Financing Activities
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Proceeds from (Payments for) Other Financing Activities of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-18.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromPaymentsForOtherFinancingActivities · last filed 2026-02-18
- ULTRAGENYX PHARMACEUTICAL INC. proceeds from (payments for) other financing activities for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. proceeds from (payments for) other financing activities for the quarter ending 2024-09-30 was $0.00.
- ULTRAGENYX PHARMACEUTICAL INC. proceeds from (payments for) other financing activities for the quarter ending 2024-06-30 was $0.00.
- ULTRAGENYX PHARMACEUTICAL INC. proceeds from (payments for) other financing activities for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. proceeds from (payments for) other financing activities for fiscal 2025 was $0.00.
- ULTRAGENYX PHARMACEUTICAL INC. proceeds from (payments for) other financing activities for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- ULTRAGENYX PHARMACEUTICAL INC. proceeds from (payments for) other financing activities for fiscal 2023 was $1.00M.
- ULTRAGENYX PHARMACEUTICAL INC. proceeds from (payments for) other financing activities for fiscal 2022 was -$555.00K.
| Period end | Proceeds from (Payments for) Other Financing Activities 3 month | Proceeds from (Payments for) Other Financing Activities 6 month | Proceeds from (Payments for) Other Financing Activities 9 month | Proceeds from (Payments for) Other Financing Activities 12 month | Proceeds from (Payments for) Other Financing Activities 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-18 | ||||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $0.00 derived: sum of 2 quarters · filed 2026-02-18 | $0.00 derived: sum of 3 quarters · filed 2026-02-18 | $0.00 10-K · filed 2026-02-18 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $0.00 derived: sum of 2 quarters · filed 2024-11-06 | $0.00 10-Q · filed 2024-11-06 | $1.03M derived: sum of 4 quarters · filed 2026-02-18 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-02 | $0.00 10-Q · filed 2024-08-02 | $1.03M derived: sum of 3 quarters · filed 2026-02-18 | $1.03M derived: sum of 4 quarters · filed 2026-02-18 | |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-03 | $1.03M derived: sum of 2 quarters · filed 2026-02-18 | $1.03M derived: sum of 3 quarters · filed 2026-02-18 | $972.00K derived: sum of 4 quarters · filed 2026-02-18 | |
| 2023-12-31 | $1.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $1.03M derived: sum of 2 quarters · filed 2026-02-18 | $972.00K derived: sum of 3 quarters · filed 2026-02-18 | $1.00M 10-K · filed 2026-02-18 | -$28.00K 10-K · filed 2024-02-21 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$56.00K derived: sum of 2 quarters · filed 2024-11-06 | -$28.00K 10-Q · filed 2024-11-06 | -$147.00K derived: sum of 4 quarters · filed 2025-02-19 | |
| 2023-06-30 | -$56.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-02 | -$28.00K 10-Q · filed 2024-08-02 | -$147.00K derived: sum of 3 quarters · filed 2025-02-19 | -$294.00K derived: sum of 4 quarters · filed 2025-02-19 | |
| 2023-03-31 | $28.00K 10-Q · filed 2024-05-03 | -$91.00K derived: sum of 2 quarters · filed 2025-02-19 | -$238.00K derived: sum of 3 quarters · filed 2025-02-19 | -$384.00K derived: sum of 4 quarters · filed 2025-02-19 | |
| 2022-12-31 | -$119.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | -$266.00K derived: sum of 2 quarters · filed 2025-02-19 | -$412.00K derived: sum of 3 quarters · filed 2025-02-19 | -$555.00K 10-K · filed 2025-02-19 | |
| 2022-09-30 | -$147.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | -$293.00K derived: sum of 2 quarters · filed 2023-11-03 | -$436.00K 10-Q · filed 2023-11-03 | -$578.00K derived: sum of 4 quarters · filed 2024-02-21 | |
| 2022-06-30 | -$146.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | -$289.00K 10-Q · filed 2023-08-04 | -$431.00K derived: sum of 3 quarters · filed 2024-02-21 | -$555.00K derived: sum of 4 quarters · filed 2024-02-21 | |
| 2022-03-31 | -$143.00K 10-Q · filed 2023-05-05 | -$285.00K derived: sum of 2 quarters · filed 2024-02-21 | -$409.00K derived: sum of 3 quarters · filed 2024-02-21 | -$523.00K derived: sum of 4 quarters · filed 2024-02-21 | |
| 2021-12-31 | -$142.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | -$266.00K derived: sum of 2 quarters · filed 2024-02-21 | -$380.00K derived: sum of 3 quarters · filed 2024-02-21 | -$492.00K 10-K · filed 2024-02-21 | |
| 2021-09-30 | -$124.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$238.00K derived: sum of 2 quarters · filed 2022-11-03 | -$350.00K 10-Q · filed 2022-11-03 | -$437.00K derived: sum of 4 quarters · filed 2023-02-17 | |
| 2021-06-30 | -$114.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-29 | -$226.00K 10-Q · filed 2022-07-29 | -$313.00K derived: sum of 3 quarters · filed 2023-02-17 | -$371.00K derived: sum of 4 quarters · filed 2023-02-17 | |
| 2021-03-31 | -$112.00K 10-Q · filed 2022-05-06 | -$199.00K derived: sum of 2 quarters · filed 2023-02-17 | -$257.00K derived: sum of 3 quarters · filed 2023-02-17 | -$315.00K derived: sum of 4 quarters · filed 2023-02-17 | |
| 2020-12-31 | -$87.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-17 | -$145.00K derived: sum of 2 quarters · filed 2023-02-17 | -$203.00K derived: sum of 3 quarters · filed 2023-02-17 | -$236.00K 10-K · filed 2023-02-17 | |
| 2020-09-30 | -$58.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | -$116.00K derived: sum of 2 quarters · filed 2021-11-03 | -$149.00K 10-Q · filed 2021-11-03 | ||
| 2020-06-30 | -$58.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | -$91.00K 10-Q · filed 2021-08-03 | |||
| 2020-03-31 | -$33.00K 10-Q · filed 2021-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |